Brain metastasis of breast cancer: A 10-year single institution retrospective analysis

Batista, Marta Vaz; Tomás, T.; Eiriz, Inês; Almeida, Susana Baptista de; Vitorino, Marina; Atalaia, G.; Rı́o, Ana del

doi:10.1093/annonc/mdz100.027

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also want to highlight the great amount of CNS metastatic involvement, which is higher than that described for all ages of BC patients, as we also saw in our previous work. 27 , 28 In a previous retrospective analysis carried out in one of the hospitals included in this study, we found, from an overall population of 217 metastatic BC patients of all ages, 21 (9.7%) with brain metastasis, with a median age of 45 years old (minimum 28 and maximum 66), which is much less than what we found in this young population (37.8%). It should be highlighted that our previous work included a large number of metastatic elderly patients.…”

Section: Discussionmentioning

confidence: 52%

Breast cancer in very young women—a multicenter 10-year experience

et al. 2021

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 52%

Breast cancer in very young women—a multicenter 10-year experience

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…The BMOS of patients with leptomeningeal metastases was shorter than that of patients with brain parenchymal metastases, consistent with a poorer prognosis (11.0 vs. 18.0 months; χ 2 =15.452, P<0.0001). Of these 33 patients, 42.4% reported no neurological symptoms, and their BMOS was longer than reported previously (30,31), potentially because these metastases were detected early due to the regular cranial MRI screening. In the present cohort, we also found that all 17 cases of spinal cord metastasis occurred following brain parenchymal/ meningeal metastasis, with no patients exhibiting spinal cord metastases in isolation.…”

Section: Discussionmentioning

confidence: 83%

“…Patients with leptomeningeal metastases have a very poor prognosis with an estimated survival of just 2-4 months (30). Batista et al (31) retrospectively conducted an analysis of MBC-BM patients over a 10-year period and found that while leptomeningeal metastases were rare, they were associated with a poorer prognosis. Znidaric et al (32) retrospectively assessed 423 breast cancer patients with brain parenchymal/meningeal metastases between 2005 and 2015.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, it is important to explore the role of systemic drug treatment for MBC-BM patients to highlight novel or more reliable diagnostic and therapeutic strategies for affected individuals. To that end, the present study was designed as a real-world clinical analysis of 559 MBC-BM patients admitted to Henan Tumor Hospital between January 1, 2010, and December 31,2019. By comparing the effectiveness of patients who received initially local or systemic treatment and the factors affecting overall survival following BM diagnosis (BMOS), we seek to provide a reference for the diagnosis and treatment of MBC-BM.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical diagnosis and treatment of breast cancer with brain metastases and establishment of a prognostic model: a 10-year, single-center, real-world study of 559 cases

Niu¹,

Lv²,

Zhang³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: This study involved a retrospective analysis of 559 metastatic breast cancer (MBC) patients with brain metastasis (BM). We aimed to establish the effectiveness of different preferred treatment methods and factors affecting overall survival following BM diagnosis (BMOS) and explore the feasibility of systemic treatment for MBC patients with BM.Methods: Univariate and multivariate analyses were used to assess the efficacy of different preferred treatments and other factors associated with BMOS, and a nomogram was then established based on the results of the univariate analysis.Results: Patients that initially received systemic drug therapy exhibited a clinical benefit rate (CBR) of 43.9% and an intracranial disease control rate (DCR) of 80.6%. The median time between BM diagnosis and the requirement for local intracranial treatment due to worsening disease status was 10.0 months for these patients (95% CI: 7.811-12.189 months). The median follow-up was 28.0 months, and the median BMOS was 16.0 months. Following BM diagnosis, the systemic drug treatment group had a better outcome than the local brain treatment group, with a respective median BMOS of 22.0 and 16.0 months (χ 2 =7.743, P=0.005).At the time of BM diagnosis, the median BMOS for patients without neurological symptoms diagnosed by regular screen was significantly longer than that of patients with neurological symptoms (18.0 vs. 13.0 months, respectively; χ 2 =11.371, P=0.001). Based on these analyses, a nomogram was constructed that incorporated disease-free survival (DFS), Karnofsky performance status (KPS), molecular subtype, number of extracranial metastases, BM location, number of BMs, neurological symptoms, and the preferred treatment approach, with a prediction probability (c-index) value of 0.76.Conclusions: Systemic drug treatment has a beneficial effect on brain lesions, and effective treatment delays the need for local intracranial treatment. Cranial magnetic resonance imaging (MRI) screening can detect asymptomatic BM in MBC patients (particularly those with HER2−positive or triple-negative disease), offering these patients an opportunity to undergo systemic drug therapy, thereby prolonging their survival.To our knowledge, this is a well-fitted nomogram including current treatment and medical examination strategies to predict BMOS probability that offers value as an adjunct for the prognostic evaluation of MBC-BM patients.

show abstract

Brain metastasis of breast cancer: A 10-year single institution retrospective analysis

Cited by 2 publications

References 0 publications

Breast cancer in very young women—a multicenter 10-year experience

Breast cancer in very young women—a multicenter 10-year experience

Clinical diagnosis and treatment of breast cancer with brain metastases and establishment of a prognostic model: a 10-year, single-center, real-world study of 559 cases

Contact Info

Product

Resources

About